Europe Fat Reduction Market - Industry Trends and Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION 211

• 1.1 OBJECTIVES OF THE STUDY 211
• 1.2 MARKET DEFINITION 211
• 1.3 OVERVIEW OF THE EUROPE FAT REDUCTION MARKET 211
• 1.4 CURRENCY AND PRICING 213
• 1.5 LIMITATIONS 213
• 1.6 MARKETS COVERED 214

2 MARKET SEGMENTATION 219

• 2.1 MARKETS COVERED 219
• 2.2 GEOGRAPHICAL SCOPE 220
• 2.3 YEARS CONSIDERED FOR THE STUDY 221
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 222
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 225
• 2.6 MULTIVARIATE MODELLING 226
• 2.7 TYPE LIFELINE CURVE 226
• 2.8 DBMR MARKET POSITION GRID 227
• 2.9 VENDOR SHARE ANALYSIS 228
• 2.10 MARKET APPLICATION COVERAGE GRID 229
• 2.11 SECONDARY SOURCES 230
• 2.12 ASSUMPTIONS 230

3 EXECUTIVE SUMMARY 231

4 PREMIUM INSIGHT 234

• 4.1 PESTEL ANALYSIS 235
• 4.2 PORTER'S FIVE FORCES 236
• 4.3 MARKET ANALYSIS 237
• 4.4 EUROPE (PRICING AND PROCEDURE ANALYSIS) 238
  • 4.4.1 GERMANY 238
  • 4.4.2 TURKEY 239
  • 4.4.3 ITALY 240
  • 4.4.4 POLAND 241
  • 4.4.5 SPAIN 242
  • 4.4.6 RUSSIA 243
  • 4.4.7 FRANCE 244
  • 4.4.8 NETHERLANDS 245
  • 4.4.9 SWITZERLAND 246
  • 4.4.10 BELIGUM 247
  • 4.4.11 AUSTRIA 248
  • 4.4.12 NORWAY 249
  • 4.4.13 IRELAND 250
  • 4.4.14 HUNGARY 251
  • 4.4.15 LITHUAMIA 252
  • 4.4.16 AZERBAIJAN 253
  • 4.4.17 U.K. 254
  • 4.4.18 GEORGIA 255
  • 4.4.19 UKRAINE 256
• 4.5 BRAND ANALYSIS 257
  • 4.5.1 KYBELLA 257
  • 4.5.2 AQUALYX 258
• 4.6 PRICING ANALYSIS (USD) 259
  • 4.6.1 EUROPE 259
    • 4.6.1.1 GERMANY 259
    • 4.6.1.2 TURKEY 259
    • 4.6.1.3 ITALY 259
    • 4.6.1.4 POLAND 260
    • 4.6.1.5 SPAIN 260
    • 4.6.1.6 RUSSIA 260
    • 4.6.1.7 FRANCE 261
    • 4.6.1.8 NETHERLANDS 261
    • 4.6.1.9 SWITZERLAND 261
    • 4.6.1.10 BELIGUM 262
    • 4.6.1.11 AUSTRIA 262
    • 4.6.1.12 NORWAY 262
    • 4.6.1.13 IRELAND 263
    • 4.6.1.14 HUNGARY 263
    • 4.6.1.15 LITHUAMIA 263
    • 4.6.1.16 AZERBAIJAN 264
    • 4.6.1.17 U.K. 264
    • 4.6.1.18 GEORGIA 264
    • 4.6.1.19 UKRAINE 265
• 4.7 PATENT ANALYSIS OF THE EUROPE FAT REDUCTION MARKET 266
  • 4.7.1 EUROPE 266
    • 4.7.1.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 266
    • 4.7.1.2 SYNTHESIS OF DEOXYCHOLIC ACID (DCA) 267
    • 4.7.1.3 METHOD AND COMPOSITION FOR REDUCING SUBCUTANEOUS FAT 268
    • 4.7.1.4 METHOD AND COMPOSITION FOR REDUCING SUBCUTANEOUS FAT DEPOSITS 269
  • 4.7.2 HUNGARY 270
    • 4.7.2.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 270
• 4.8 PRICING ANALYSIS (USD) 271
  • 4.8.1 KYBELLA 271
  • 4.8.2 COOLSCULPTING 273
  • 4.8.3 COOLSCULPTING ELITE 275
  • 4.8.4 COOLTONE 277

5 INDUSTRY INSIGHTS: 280

• 5.1 DEMOGRAPHIC TRENDS: 281
• 5.2 CONCLUSION: 282

6 EUROPE FAT REDUCTION MARKET, REGULATIONS 283

• 6.1 DOMINICAN REPUBLIC 283
  • 6.1.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 283
  • 6.1.2 RENEWAL OF REGISTRATION IS REQUIRED IF THERE IS A CHANGE IN PRODUCT FORMULATION OR A CHANGE IN THE SITE OF MANUFACTURE. 284
  • 6.1.3 TIMELINE 284
• 6.2 GUATEMALA 285
  • 6.2.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 285
  • 6.2.2 REGULATORY APPROVAL AGENCIES 285
  • 6.2.3 LICENSING AND REGISTRATION 286
  • 6.2.4 POST-MARKETING SURVEILLANCE 286
  • 6.2.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 286
• 6.3 HONDURAS 286
  • 6.3.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 286
  • 6.3.2 REGULATORY APPROVAL AGENCIES 286
• 6.4 NICARAGUA 287
  • 6.4.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 287
  • 6.4.2 LICENSING AND REGISTRATION 287
  • 6.4.3 POST-MARKETING SURVEILLANCE 287
• 6.5 GERMANY 287
  • 6.5.1 REGULATORY APPROVAL AGENCIES AND PROCESS 287
• 6.6 FRANCE 288
  • 6.6.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 288
  • 6.6.2 REGULATORY APPROVAL AGENCIES 288
  • 6.6.3 POST-MARKETING SURVEILLANCE 288
• 6.7 U.K. 288
  • 6.7.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 288
  • 6.7.2 GENERIC MARKET 289
  • 6.7.3 REGULATORY APPROVAL AGENCIES 289
  • 6.7.4 LICENSING AND REGISTRATION 290
  • 6.7.5 POST-MARKETING SURVEILLANCE 291
• 6.8 ITALY 291
  • 6.8.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 291
  • 6.8.2 REGULATORY APPROVAL AGENCIES 291
  • 6.8.3 LICENSING AND REGISTRATION 292
  • 6.8.4 POST-MARKETING SURVEILLANCE 292
  • 6.8.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 292
• 6.9 SPAIN 292
  • 6.9.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 292
  • 6.9.2 REGULATORY APPROVAL AGENCIES 292
  • 6.9.3 LICENSING AND REGISTRATION 292
• 6.10 RUSSIA 293
  • 6.10.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 293
  • 6.10.2 TIMELINE 293
  • 6.10.3 REGULATORY APPROVAL AGENCIES 293
  • 6.10.4 LICENSING AND REGISTRATION 293
  • 6.10.5 GOOD MANUFACTURING PRACTICES 294
  • 6.10.6 TIMELINES FOR RUSSIAN GMP CERTIFICATE 294
• 6.11 TURKEY 295
  • 6.11.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 295
  • 6.11.2 REGULATORY APPROVAL AGENCIES 295
  • 6.11.3 LICENSING AND REGISTRATION 295
  • 6.11.4 POST-MARKETING SURVEILLANCE 296
  • 6.11.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 296
• 6.12 AZERBAIJAN 296
  • 6.12.1 THE FOLLOWING TERMS ARE USED IN THE PRESENT REGULATIONS: 296
  • 6.12.2 PROCEDURE OF SUBMITTING FOR STATE REGISTRATION 297
  • 6.12.3 LICENSING 298
• 6.13 UKRAINE 298
  • 6.13.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 298
  • 6.13.2 REGULATORY APPROVAL AGENCIES 298
  • 6.13.3 LICENSING AND REGISTRATION 299
  • 6.13.4 POST-MARKETING SURVEILLANCE 300
• 6.14 BELGIUM 301
  • 6.14.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 301
  • 6.14.2 REGULATORY APPROVAL AGENCIES 301
  • 6.14.3 LICENSING AND REGISTRATION 301
• 6.15 HUNGARY 301
  • 6.15.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 301
  • 6.15.2 REGULATORY APPROVAL AGENCIES 301
  • 6.15.3 LICENSING AND REGISTRATION 302
  • 6.15.4 POST-MARKETING SURVEILLANCE 302
• 6.16 LITHUANIA 302
  • 6.16.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 302
  • 6.16.2 REGULATORY APPROVAL AGENCIES 303
• 6.17 AUSTRIA 303
  • 6.17.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 303
  • 6.17.2 REGULATORY APPROVAL AGENCIES 303
  • 6.17.3 LICENSING AND REGISTRATION 303
  • 6.17.4 POST-MARKETING SURVEILLANCE 303
• 6.18 IRELAND 304
  • 6.18.1 REGULATORY APPROVAL AGENCIES 304
• 6.19 NORWAY 305
  • 6.19.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 305
• 6.20 NETHERLANDS 306
  • 6.20.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 306
• 6.21 SWITZERLAND 306
  • 6.21.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 306

7 PIPELINE ANALYSIS OF THE EUROPE FAT REDUCTION MARKET 307

8 MARKET ACCESS 314

• 8.1 MANUFACTURER AND STRATEGIC DEALS 314
• 8.2 CURRENT TREATMENT PRACTICES 314
• 8.3 IMPACT OF UPCOMING THERAPY 315

9 MARKET OVERVIEW 316

• 9.1 DRIVERS 318
  • 9.1.1 INCREASING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES 318
  • 9.1.2 GROWING AESTHETIC CONSCIOUSNESS AND BEAUTY STANDARDS 319
  • 9.1.3 GROWING TECHNOLOGICAL ADVANCEMENTS 320
  • 9.1.4 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR AESTHETIC PROCEDURES 321
• 9.2 RESTRAINTS 322
  • 9.2.1 HIGH COST OF PROCEDURES 322
  • 9.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 323
  • 9.2.3 PRODUCT RECALL 323
• 9.3 OPPORTUNITIES 324
  • 9.3.1 CUSTOMIZED TREATMENT PLANS AND INTEGRATION WITH OTHER AESTHETIC PROCEDURES 324
  • 9.3.2 BELIEF AND TREND OF FAT REDUCTION IN YOUNG ADULTS 325
  • 9.3.3 FOCUS ON INCLUSIVITY AND DIVERSITY AND EXPANSION OF PRODUCT LINES 327
• 9.4 CHALLENGES 329
  • 9.4.1 LONG-TERM EFFICACY AND SUSTAINABILITY 329
  • 9.4.2 LONGER RECOVERY TIME OF THE PROCEDURE 329

10 EUROPE FAT REDUCTION MARKET, BY TYPE 331

• 10.1 OVERVIEW 332
• 10.2 SURGICAL FAT REDUCTION 335
  • 10.2.1 LIPOSUCTION 336
    • 10.2.1.1 BY TYPE 337
      • 10.2.1.1.1 ULTRASOUND-ASSISTED LIPOSUCTION 337
      • 10.2.1.1.2 LASER-ASSISTED LIPOSUCTION 338
      • 10.2.1.1.3 TUMESCENT LIPOSUCTION 338
      • 10.2.1.1.4 SUPER-WET TECHNIQUE 338
    • 10.2.1.2 BY APPLICATION 338
      • 10.2.1.2.1 ABDOMINAL FAT 339
      • 10.2.1.2.2 THIGHS FAT 339
      • 10.2.1.2.3 BUTTOCK FAT 339
      • 10.2.1.2.4 UPPER-ARM FAT 339
      • 10.2.1.2.5 FACIAL FAT-DEPOSITS 339
      • 10.2.1.2.5.1 SUBMENTAL AREAS 340
      • 10.2.1.2.5.2 MALAR 340
      • 10.2.1.2.5.3 MANDIBULAR 340
      • 10.2.1.2.6 KNEE FAT 340
  • 10.2.2 SURGICAL REJUVENATION 340
    • 10.2.2.1 FACE LIFT 341
    • 10.2.2.2 NECK LIFT 341
  • 10.2.3 CHIN IMPLANT 341
    • 10.2.3.1 SILICONE CHIN IMPLANTS 342
    • 10.2.3.2 OTHERS 342
  • 10.2.4 PORUS IMPLANTS 342
    • 10.2.4.1 TEFLON 343
    • 10.2.4.2 GORE-TEX 343
    • 10.2.4.3 MEDPORE IMPLANTS 343
• 10.3 NON-INVASIVE FAT REDUCTION 343
  • 10.3.1 CRYOLIPOLYSIS 346
    • 10.3.1.1 COOL SCULPTING 346
    • 10.3.1.2 COOL SCULPTING ELITE 346
    • 10.3.1.3 COOL TONE 347
    • 10.3.1.4 OTHERS 347
      • 10.3.1.4.1 ABDOMINAL FAT 347
      • 10.3.1.4.2 THIGHS FAT 347
      • 10.3.1.4.3 BUTTOCK FAT 348
      • 10.3.1.4.4 UPPER-ARM FAT 348
      • 10.3.1.4.5 FACIAL FAT-DEPOSITS 348
      • 10.3.1.4.6 KNEE FAT 348
  • 10.3.2 ULTRASOUND 348
    • 10.3.2.1 INTERNAL ULTRASONIC LIPOSUCTION 349
    • 10.3.2.2 EXTERNAL ULTRASONIC LIPOSUCTION 349
      • 10.3.2.2.1 ABDOMINAL FAT 350
      • 10.3.2.2.2 THIGHS FAT 350
      • 10.3.2.2.3 BUTTOCK FAT 350
      • 10.3.2.2.4 UPPER-ARM FAT 350
      • 10.3.2.2.5 FACIAL FAT-DEPOSITS 350
      • 10.3.2.2.6 KNEE FAT 350
  • 10.3.3 RADIOFREQUENCY 351
    • 10.3.3.1 ABDOMINAL FAT 351
    • 10.3.3.2 THIGHS FAT 351
    • 10.3.3.3 BUTTOCK FAT 351
    • 10.3.3.4 UPPER-ARM FAT 351
    • 10.3.3.5 FACIAL FAT-DEPOSITS 352
    • 10.3.3.6 KNEE FAT 352

• 10.3.4 LOW LEVEL LASER THERAPY 352
  • 10.3.4.1 ABDOMINAL FAT 352
  • 10.3.4.2 THIGHS FAT 352
  • 10.3.4.3 BUTTOCK FAT 353
  • 10.3.4.4 UPPER-ARM FAT 353
  • 10.3.4.5 FACIAL FAT-DEPOSITS 353
  • 10.3.4.6 KNEE FAT 353
• 10.3.5 OTHERS 353
• 10.4 MINIMALLY INVASIVE 353
  • 10.4.1 INJECTION LIPOLYSIS 355
    • 10.4.1.1 DEOXYCHOLIC ACID INJECTIONS 355
      • 10.4.1.1.1 KYBELLA/BELKYRA 356
      • 10.4.1.1.1.1 FACIAL FAT-DEPOSITS 357
      • 10.4.1.1.1.2 UPPER-ARM FAT 357
      • 10.4.1.1.1.3 ABDOMINAL FAT 357
      • 10.4.1.1.1.4 THIGHS FAT 357
      • 10.4.1.1.1.5 KNEE FAT 357
      • 10.4.1.1.1.6 BUTTOCK FAT 357
      • 10.4.1.1.2 AQUALYX 358
      • 10.4.1.1.2.1 FACIAL FAT-DEPOSITS 358
      • 10.4.1.1.2.2 UPPER-ARM FAT 358
      • 10.4.1.1.2.3 ABDOMINAL FAT 358
      • 10.4.1.1.2.4 THIGHS FAT 359
      • 10.4.1.1.2.5 KNEE FAT 359
      • 10.4.1.1.2.6 BUTTOCK FAT 359
    • 10.4.1.2 PHOSPHATIDYLCHOLINE 359
      • 10.4.1.2.1 FACIAL FAT-DEPOSITS 360
      • 10.4.1.2.2 UPPER-ARM FAT 360
      • 10.4.1.2.3 ABDOMINAL FAT 360
      • 10.4.1.2.4 THIGHS FAT 360
      • 10.4.1.2.5 KNEE FAT 360
      • 10.4.1.2.6 BUTTOCK FAT 360
    • 10.4.1.3 OTHERS 360
  • 10.4.2 OTHERS 360

11 EUROPE FAT REDUCTION MARKET, BY APPLICATION 361

• 11.1 OVERVIEW 362
• 11.2 ABDOMINAL FAT 365
• 11.3 THIGHS FAT 366
• 11.4 BUTTOCK FAT 367
• 11.5 UPPER-ARM FAT 368
• 11.6 FACIAL FAT-DEPOSITS 369
  • 11.6.1 SUBMENTAL AREAS 370
  • 11.6.2 MANDIBULAR 370
  • 11.6.3 MALAR 370
• 11.7 KNEE FAT 370

12 EUROPE FAT REDUCTION MARKET, BY GENDER 372

• 12.1 OVERVIEW 373
• 12.2 FEMALE 376
• 12.3 MALE 377

13 EUROPE FAT REDUCTION MARKET, BY AGE GROUP 378

• 13.1 OVERVIEW 379
• 13.2 ADULT 382
• 13.3 GERIATRIC 383
• 13.4 CHILD 384

14 EUROPE FAT REDUCTION MARKET, BY END USER 386

• 14.1 OVERVIEW 387
• 14.2 HOSPITALS 390
  • 14.2.1 BY TYPE 391
    • 14.2.1.1 PRIVATE 391
    • 14.2.1.2 PUBLIC 391
  • 14.2.2 BY CATEGORY 391
    • 14.2.2.1 TIER 1 392
    • 14.2.2.2 TIER 2 392
    • 14.2.2.3 TIER 3 392
• 14.3 MULTISPECIALTY CLINICS 392
• 14.4 DERMATOLOGY CENTERS 393
• 14.5 MEDICAL SPAS AND BEAUTY CENTERS 394
• 14.6 OTHERS 395

15 EUROPE FAT REDUCTION MARKET, BY DISTRIBUTION CHANNEL 397

• 15.1 OVERVIEW 398
• 15.2 DIRECT TENDERS 401
• 15.3 RETAIL SALES 402
• 15.4 THIRD PARTY DISTRIBUTORS 403
• 15.5 OTHERS 404

16 EUROPE FAT REDUCTION MARKET, BY REGION 405

• 16.1 EUROPE 406
  • 16.1.1 GERMANY 427
  • 16.1.2 TURKEY 446
  • 16.1.3 ITALY 465
  • 16.1.4 POLAND 484
  • 16.1.5 SPAIN 503
  • 16.1.6 RUSSIA 521
  • 16.1.7 FRANCE 538
  • 16.1.8 NETHERLANDS 556
  • 16.1.9 SWITZERLAND 575
  • 16.1.10 BELGIUM 594
  • 16.1.11 AUSTRIA 612
  • 16.1.12 NORWAY 631
  • 16.1.13 IRELAND 649
  • 16.1.14 HUNGARY 667
  • 16.1.15 LITHUANIA 684
  • 16.1.16 AZERBAIJAN 702
  • 16.1.17 U.K. 719
  • 16.1.18 GEORGIA 735
  • 16.1.19 UKRAINE 752
  • 16.1.20 REST OF EUROPE 770

17 EUROPE FAT REDUCTION MARKET, COMPANY LANDSCAPE 771

• 17.1 COMPANY SHARE ANALYSIS: EUROPE 771

18 EUROPE FAT REDUCTION MARKET, COMPANY LANDSCAPE COUNTRY WISE 772

• 18.1 COMPANY SHARE ANALYSIS: EUROPE 772
  • 18.1.1 COMPANY SHARE ANALYSIS: GERMANY 772
    • 18.1.1.1 ABBVIE INC. 773
    • 18.1.1.2 CYNOSURE 774
    • 18.1.1.3 ALMA LASERS 775
    • 18.1.1.4 CANDELA CORPORATION 776
    • 18.1.1.5 MERZ PHARMA 777
  • 18.1.2 COMPANY SHARE ANALYSIS: FRANCE 778
    • 18.1.2.1 COMPANY SHARE ANALYSIS: FRANCE 778
    • 18.1.2.2 ABBVIE INC. 779
    • 18.1.2.3 CYNOSURE 780
    • 18.1.2.4 CANDELA CORPORATION 781
    • 18.1.2.5 VENUS CONCEPT 782
  • 18.1.3 COMPANY SHARE ANALYSIS: U.K 783
    • 18.1.3.1 COMPANY SHARE ANALYSIS: U.K 783
    • 18.1.3.2 ABBVIE INC. 784
    • 18.1.3.3 CYNOSURE 785
    • 18.1.3.4 ALMA LASERS 786
    • 18.1.3.5 CANDELA CORPORATION 787
    • 18.1.3.6 MERZ PHARMA 788
  • 18.1.4 COMPANY SHARE ANALYSIS: ITALY 789
    • 18.1.4.1 COMPANY SHARE ANALYSIS: ITALY 789
    • 18.1.4.2 ABBVIE INC. 790
    • 18.1.4.3 CANDELA CORPORATION 791
    • 18.1.4.4 MERZ PHARMA 792
    • 18.1.4.5 MENTOR WORLDWIDE LLC 793
  • 18.1.5 COMPANY SHARE ANALYSIS: SPAIN 794
    • 18.1.5.1 COMPANY SHARE ANALYSIS: SPAIN 794
    • 18.1.5.2 ABBVIE INC. 795
    • 18.1.5.3 CYNOSURE 796
    • 18.1.5.4 CANDELA CORPORATION 797
  • 18.1.6 COMPANY SHARE ANALYSIS: RUSSIA 798
    • 18.1.6.1 COMPANY SHARE ANALYSIS: RUSSIA 798
    • 18.1.6.2 ABBVIE INC. 799
    • 18.1.6.3 CANDELA CORPORATION 800
    • 18.1.6.4 MERZ PHARMA 801
    • 18.1.6.5 MENTOR WORLDWIDE LLC 802
  • 18.1.7 COMPANY SHARE ANALYSIS: TURKEY 803
    • 18.1.7.1 COMPANY SHARE ANALYSIS: TURKEY 803
    • 18.1.7.2 ABBVIE INC. 804
    • 18.1.7.3 CANDELA CORPORATION 805
  • 18.1.8 COMPANY SHARE ANALYSIS: POLAND 806
    • 18.1.8.1 COMPANY SHARE ANALYSIS: POLAND 806
    • 18.1.8.2 ABBVIE INC. 807
    • 18.1.8.3 CANDELA CORPORATION 808
  • 18.1.9 COMPANY SHARE ANALYSIS: UKARINE 809
    • 18.1.9.1 COMPANY SHARE ANALYSIS: UKARINE 809
    • 18.1.9.2 ABBVIE INC. 810
    • 18.1.9.3 CANDELA CORPORATION 811
  • 18.1.10 COMPANY SHARE ANALYSIS: BELGIUM 812
    • 18.1.10.1 COMPANY SHARE ANALYSIS: BELGIUM 812
    • 18.1.10.2 ABBVIE INC. 813
    • 18.1.10.3 CANDELA CORPORATION 814
  • 18.1.11 COMPANY SHARE ANALYSIS: HUNGARY 815
    • 18.1.11.1 COMPANY SHARE ANALYSIS: HUNGARY 815
    • 18.1.11.2 ABBVIE INC. 816
    • 18.1.11.3 CANDELA CORPORATION 817
  • 18.1.12 COMPANY SHARE ANALYSIS: AUSTRIA 818
    • 18.1.12.1 COMPANY SHARE ANALYSIS: AUSTRIA 818
    • 18.1.12.2 ABBVIE INC. 819
    • 18.1.12.3 MENTOR WORLDWIDE LLC 820
  • 18.1.13 COMPANY SHARE ANALYSIS: IRELAND 821
    • 18.1.13.1 COMPANY SHARE ANALYSIS: IRELAND 821
    • 18.1.13.2 ABBVIE INC. 822
  • 18.1.14 COMPANY SHARE ANALYSIS: NORWAY 823
    • 18.1.14.1 COMPANY SHARE ANALYSIS: NORWAY 823
    • 18.1.14.2 ABBVIE INC. 824
    • 18.1.14.3 CANDELA CORPORATION 825
  • 18.1.15 COMPANY SHARE ANALYSIS: NETHERLAND 826
    • 18.1.15.1 COMPANY SHARE ANALYSIS: NETHERLAND 826
    • 18.1.15.2 ABBVIE INC. 827
    • 18.1.15.3 CANDELA CORPORATION 828
    • 18.1.15.4 MERZ PHARMA 829
    • 18.1.15.5 MENTOR WORLDWIDE LLC 830
  • 18.1.16 COMPANY SHARE ANALYSIS: SWITZERLAND 831
    • 18.1.16.1 COMPANY SHARE ANALYSIS: SWITZERLAND 831
    • 18.1.16.2 ABBVIE INC. 832
    • 18.1.16.3 MERZ PHARMA 833
    • 18.1.16.4 MENTOR WORLDWIDE LLC 834
  • 18.1.17 COMPANY SHARE ANALYSIS: AZERBAIJAN 835
    • 18.1.17.1 COMPANY SHARE ANALYSIS: AZERBAIJAN 835
    • 18.1.17.2 CANDELA CORPORATION 836
  • 18.1.18 COMPANY SHARE ANALYSIS: GEORGIA 837
    • 18.1.18.1 COMPANY SHARE ANALYSIS: GEORGIA 837
    • 18.1.18.2 CANDELA CORPORATION 838
  • 18.1.19 COMPANY SHARE ANALYSIS: LITHUANIA 839
    • 18.1.19.1 COMPANY SHARE ANALYSIS: LITHUANIA 839
    • 18.1.19.2 CANDELA CORPORATION 840

19 SWOT ANALYSIS 841

20 EUROPE FAT REDUCTION MARKET, COMPANY PROFILINGS 842

• 20.1 ABBVIE INC.(2022) 842
  • 20.1.1 COMPANY SNAPSHOT 842
  • 20.1.2 REVENUE ANALYSIS 842
  • 20.1.3 COMPANY SHARE ANALYSIS 843
  • 20.1.4 PRODUCT PORTFOLIO 843
  • 20.1.5 RECENT DEVELOPMENTS 844
• 20.2 CYNOSURE 845
  • 20.2.1 COMPANY SNAPSHOT 845
  • 20.2.2 COMPANY SHARE ANALYSIS 845
  • 20.2.3 PRODUCT PORTFOLIO 846
  • 20.2.4 RECENT DEVELOPMENTS 846
• 20.3 ALMA LASERS 847
  • 20.3.1 COMPANY SNAPSHOT 847
  • 20.3.2 COMPANY SHARE ANALYSIS 847
  • 20.3.3 PRODUCT PORTFOLIO 848
  • 20.3.4 RECENT DEVELOPMENT 848
• 20.4 CANDELA CORPORATION 849
  • 20.4.1 COMPANY SNAPSHOT 849
  • 20.4.2 COMPANY SHARE ANALYSIS 849
  • 20.4.3 PRODUCT PORTFOLIO 850
  • 20.4.4 RECENT DEVELOPMENT 850
• 20.5 MERZ NORTH AMERICA, INC. 851
  • 20.5.1 COMPANY SNAPSHOT 851
  • 20.5.2 COMPANY SHARE ANALYSIS 851
  • 20.5.3 PRODUCT PORTFOLIO 852
  • 20.5.4 RECENT DEVELOPMENTS 852
• 20.6 3D AESTHETICS 853
  • 20.6.1 COMPANY SNAPSHOT 853
  • 20.6.2 PRODUCT PORTFOLIO 853
  • 20.6.3 RECENT DEVELOPMENT 853
• 20.7 ADVIN HEALTH CARE 854
  • 20.7.1 COMPANY SNAPSHOT 854
  • 20.7.2 PRODUCT PORTFOLIO 854
  • 20.7.3 RECENT DEVELOPMENT 854
• 20.8 BLACK & BLACK SURGICAL 855
  • 20.8.1 COMPANY SNAPSHOT 855
  • 20.8.2 PRODUCT PORTFOLIO 855
  • 20.8.3 RECENT DEVELOPMENT 855
• 20.9 BTL GROUP OF COMPANIES 856
  • 20.9.1 COMPANY SNAPSHOT 856
  • 20.9.2 PRODUCT PORTFOLIO 856
  • 20.9.3 RECENT DEVELOPMENTS 856
• 20.10 BAUSCH HEALTH COMPANIES INC. 857
  • 20.10.1 COMPANY SNAPSHOT 857
  • 20.10.2 REVENUE ANALYSIS 857
  • 20.10.3 PRODUCT PORTFOLIO 858
  • 20.10.4 RECENT DEVELOPMENT 858
• 20.11 CUTERA (2022) 859
  • 20.11.1 COMPANY SNAPSHOT 859
  • 20.11.2 REVENUE ANALYSIS 859
  • 20.11.3 PRODUCT PORTFOLIO 860
  • 20.11.4 RECENT DEVELOPMENT 860
• 20.12 DEXLEVOAESTHETIC 861
  • 20.12.1 COMPANY SNAPSHOT 861
  • 20.12.2 PRODUCT PORTFOLIO 861
  • 20.12.3 RECENT DEVELOPMENT 861
• 20.13 ERCHONIA CORPORATION 862
  • 20.13.1 COMPANY SNAPSHOT 862
  • 20.13.2 PRODUCT PORTFOLIO 862
  • 20.13.3 RECENT DEVELOPMENT 862

• 20.14 FOTONA 863
  • 20.14.1 COMPANY SNAPSHOT 863
  • 20.14.2 PRODUCT PORTFOLIO 863
  • 20.14.3 RECENT DEVELOPMENT 863
• 20.15 GENESIS BIOSYSTEMS, INC. 864
  • 20.15.1 COMPANY SNAPSHOT 864
  • 20.15.2 PRODUCT PORTFOLIO 864
  • 20.15.3 RECENT DEVELOPMENT 864
• 20.16 HIRONIC CO., LTD. 865
  • 20.16.1 COMPANY SNAPSHOT 865
  • 20.16.2 REVENUE ANALYSIS 865
  • 20.16.3 PRODUCT PORTFOLIO 866
  • 20.16.4 RECENT DEVELOPMENT 866
• 20.17 IMPLANTECH 867
  • 20.17.1 COMPANY SNAPSHOT 867
  • 20.17.2 PRODUCT PORTFOLIO 867
  • 20.17.3 RECENT DEVELOPMENTS 868
• 20.18 INTROPHARMA 869
  • 20.18.1 COMPANY SNAPSHOT 869
  • 20.18.2 PRODUCT PORTFOLIO 869
  • 20.18.3 RECENT DEVELOPMENT 869
• 20.19 LEADERMA INC. 870
  • 20.19.1 COMPANY SNAPSHOT 870
  • 20.19.2 PRODUCT PORTFOLIO 870
  • 20.19.3 RECENT DEVELOPMENT 870
• 20.20 LYNTON LASERS LTD 871
  • 20.20.1 COMPANY SNAPSHOT 871
  • 20.20.2 PRODUCT PORTFOLIO 871
  • 20.20.3 RECENT DEVELOPMENT 871
• 20.21 MENTOR WORLDWIDE LLC (A PART OF JOHNSON & JOHNSON SERVICES, INC.) 872
  • 20.21.1 COMPANY SNAPSHOT 872
  • 20.21.2 REVENUE ANALYSIS 872
  • 20.21.3 PRODUCT PORTFOLIO 873
  • 20.21.4 RECENT DEVELOPMENT 873
• 20.22 MICROAIRE SURGICAL INSTRUMENTS, LLC. 874
  • 20.22.1 COMPANY SNAPSHOT 874
  • 20.22.2 PRODUCT PORTFOLIO 874
  • 20.22.3 RECENT DEVELOPMENT 874
• 20.23 MOLLER MEDICAL 875
  • 20.23.1 COMPANY SNAPSHOT 875
  • 20.23.2 PRODUCT PORTFOLIO 875
  • 20.23.3 RECENT DEVELOPMENT 875
• 20.24 POLLOGEN (A SUBSIDIARY OF LUMENIS BE LTD.) 876
  • 20.24.1 COMPANY SNAPSHOT 876
  • 20.24.2 PRODUCT PORTFOLIO 876
  • 20.24.3 RECENT DEVELOPMENT 876
• 20.25 SILIMED 877
  • 20.25.1 COMPANY SNAPSHOT 877
  • 20.25.2 PRODUCT PORTFOLIO 877
  • 20.25.3 RECENT DEVELOPMENTS 877
• 20.26 SURGIFORM INNOVATIVE SURGICAL PRODUCTS 878
  • 20.26.1 COMPANY SNAPSHOT 878
  • 20.26.2 PRODUCT PORTFOLIO 878
  • 20.26.3 RECENT DEVELOPMENT 878
• 20.27 VENUS CONCEPT 879
  • 20.27.1 COMPANY SNAPSHOT 879
  • 20.27.2 REVENUE ANALYSIS 879
  • 20.27.3 PRODUCT PORTFOLIO 880
  • 20.27.4 RECENT DEVELOPMENT 880

21 QUESTIONNAIRE 881

22 RELATED REPORTS 885

LIST OF FIGURES

• FIGURE 1 EUROPE FAT REDUCTION MARKET: SEGMENTATION 82
• FIGURE 2 EUROPE FAT REDUCTION MARKET: DATA TRIANGULATION 85
• FIGURE 3 EUROPE FAT REDUCTION MARKET: DROC ANALYSIS 86
• FIGURE 4 EUROPE FAT REDUCTION MARKET: EUROPE VS. REGIONAL MARKET ANALYSIS 87
• FIGURE 5 EUROPE FAT REDUCTION MARKET: COMPANY RESEARCH ANALYSIS 87
• FIGURE 6 EUROPE FAT REDUCTION MARKET: INTERVIEW DEMOGRAPHICS 88
• FIGURE 7 EUROPE FAT REDUCTION MARKET: MULTIVARIATE MODELLING 89
• FIGURE 8 EUROPE FAT REDUCTION MARKET: DBMR MARKET POSITION GRID 90
• FIGURE 9 EUROPE FAT REDUCTION MARKET: VENDOR SHARE ANALYSIS 91
• FIGURE 10 EUROPE FAT REDUCTION MARKET: MARKET APPLICATION COVERAGE GRID 92
• FIGURE 11 EUROPE FAT REDUCTION MARKET: SEGMENTATION 96
• FIGURE 12 INCREASING DEMAND FOR NON-INVASIVE AND MINIMALLY INVASIVE AESTHETIC PROCEDURES IS EXPECTED TO DRIVE THE EUROPE FAT REDUCTION MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2033 97
• FIGURE 13 THE SURGICAL FAT REDUCTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE FAT REDUCTION MARKET IN 2023 & 2033 97
• FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE FAT REDUCTION MARKET 180
• FIGURE 15 EUROPE FAT REDUCTION MARKET: BY TYPE, 2022 195
• FIGURE 16 EUROPE FAT REDUCTION MARKET: BY TYPE, 2023-2033 (USD MILLION) 196
• FIGURE 17 EUROPE FAT REDUCTION MARKET: BY TYPE, CAGR (2023-2033) 196
• FIGURE 18 EUROPE FAT REDUCTION MARKET: BY TYPE, LIFELINE CURVE 197
• FIGURE 19 EUROPE FAT REDUCTION MARKET: BY APPLICATION, 2022 225
• FIGURE 20 EUROPE FAT REDUCTION MARKET: BY APPLICATION, 2023-2033 (USD MILLION) 226
• FIGURE 21 EUROPE FAT REDUCTION MARKET: BY APPLICATION, CAGR (2023-2033) 226
• FIGURE 22 EUROPE FAT REDUCTION MARKET: BY APPLICATION, LIFELINE CURVE 227
• FIGURE 23 EUROPE FAT REDUCTION MARKET: BY GENDER, 2022 236
• FIGURE 24 EUROPE FAT REDUCTION MARKET: BY GENDER, 2023-2033 (USD MILLION) 237
• FIGURE 25 EUROPE FAT REDUCTION MARKET: BY GENDER, CAGR (2023-2033) 237
• FIGURE 26 EUROPE FAT REDUCTION MARKET: BY GENDER, LIFELINE CURVE 238
• FIGURE 27 EUROPE FAT REDUCTION MARKET: BY AGE GROUP, 2022 242
• FIGURE 28 EUROPE FAT REDUCTION MARKET: BY AGE GROUP, 2023-2033 (USD MILLION) 243
• FIGURE 29 EUROPE FAT REDUCTION MARKET: BY AGE GROUP, CAGR (2023-2033) 243
• FIGURE 30 EUROPE FAT REDUCTION MARKET: BY AGE GROUP, LIFELINE CURVE 244
• FIGURE 31 EUROPE FAT REDUCTION MARKET: BY END USER, 2022 250
• FIGURE 32 EUROPE FAT REDUCTION MARKET: BY END USER, 2023-2033 (USD MILLION) 251
• FIGURE 33 EUROPE FAT REDUCTION MARKET: BY END USER, CAGR (2023-2033) 251
• FIGURE 34 EUROPE FAT REDUCTION MARKET: BY END USER, LIFELINE CURVE 252
• FIGURE 35 EUROPE FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, 2022 261
• FIGURE 36 EUROPE FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, 2023-2033 (USD MILLION) 262
• FIGURE 37 EUROPE FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2033) 262
• FIGURE 38 EUROPE FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 263
• FIGURE 39 EUROPE FAT REDUCTION MARKET: SNAPSHOT (2022) 270
• FIGURE 40 EUROPE FAT REDUCTION MARKET: BY COUNTRY (2022) 271
• FIGURE 41 EUROPE FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 271
• FIGURE 42 EUROPE FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 272
• FIGURE 43 EUROPE FAT REDUCTION MARKET: BY TYPE (2023-2033) 272
• FIGURE 44 EUROPE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 634
• FIGURE 45 THE GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 635
• FIGURE 46 ABBVIE INC.IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 636
• FIGURE 47 CYNOSURE IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 637
• FIGURE 48 ALMA LASERS IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 638
• FIGURE 49 CANDELA CORPORATION IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 639
• FIGURE 50 MERZ PHARMA IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 640
• FIGURE 51 THE FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 641
• FIGURE 52 ABBVIE INC.IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 642
• FIGURE 53 CYNOSURE IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 643
• FIGURE 54 CANDELA CORPORATION IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 644
• FIGURE 55 VENOUS CONCEPT IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 645
• FIGURE 56 THE U.K. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 646
• FIGURE 57 ABBVIE INC.IN U.K. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 647
• FIGURE 58 CYNOSURE IN U.K. IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 648
• FIGURE 59 ALMA LASERS IN U.K FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 649
• FIGURE 60 CANDELA CORPORATION IN U.K. IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 650
• FIGURE 61 MERZ PHARMA IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 651
• FIGURE 62 THE ITALY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 652
• FIGURE 63 ABBVIE INC.IN ITALY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 653
• FIGURE 64 CANDELA CORPORATION IN ITALY IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 654
• FIGURE 65 MERZ PHARMA IN ITALY IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 655
• FIGURE 66 MENTOR WORLDWIDE LLC IN BRAZIL FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 656
• FIGURE 67 THE SPAIN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 657
• FIGURE 68 ABBVIE INC.IN SPAIN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 658
• FIGURE 69 CYNOSURE IN SPAIN IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 659
• FIGURE 70 CANDELA CORPORATION IN SPAIN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 660
• FIGURE 71 THE RUSSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 661
• FIGURE 72 ABBVIE INC.IN RUSSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 662
• FIGURE 73 CANDELA CORPORATION IN RUSSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 663
• FIGURE 74 MERZ PHARMA IN RUSSIA IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 664
• FIGURE 75 MENTOR WORLDWIDE LLC IN RUSSIA IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 665
• FIGURE 76 THE TURKEY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 666
• FIGURE 77 ABBVIE INC.IN TURKEY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 667
• FIGURE 78 CANDELA CORPORATION IN TURKEY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 668
• FIGURE 79 THE POLAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 669
• FIGURE 80 ABBVIE INC.IN POLAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 670
• FIGURE 81 CANDELA CORPORATION IN POLAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 671
• FIGURE 82 THE UKARINE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 672
• FIGURE 83 ABBVIE INC.IN UKARINE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 673
• FIGURE 84 CANDELA CORPORATION IN UKARINE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 674
• FIGURE 85 THE BELGIUM FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 675
• FIGURE 86 ABBVIE INC.IN BELGIUM FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 676
• FIGURE 87 CANDELA CORPORATION IN BELGIUM FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 677
• FIGURE 88 HUNGARY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 678
• FIGURE 89 ABBVIE INC.IN HUNGARY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 679
• FIGURE 90 CANDELA CORPORATION IN HUNGARY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 680
• FIGURE 91 AUSTRIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 681
• FIGURE 92 ABBVIE INC.IN AUSTRIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 682
• FIGURE 93 MENTOR WORLDWIDE LLC IN RUSSIA IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 683
• FIGURE 94 IRELAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 684
• FIGURE 95 ABBVIE INC.IN IRELAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 685
• FIGURE 96 NORWAY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 686
• FIGURE 97 ABBVIE INC.IN NORWAY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 687
• FIGURE 98 CANDELA CORPORATION IN NORWAY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 688
• FIGURE 99 NETHERLAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 689
• FIGURE 100 ABBVIE INC.IN NETHERLNDS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 690
• FIGURE 101 CANDELA CORPORATION IN NETHERLANDS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 691
• FIGURE 102 MERZ PHARMA IN NETHERLANDS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 692
• FIGURE 103 MENTOR WORLDWIDE LLC IN RUSSIA IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 693
• FIGURE 104 SWITZERLAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 694
• FIGURE 105 ABBVIE INC.IN SWITZERLAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 695
• FIGURE 106 MERZ PHARMA IN SWITZERLAND FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 696
• FIGURE 107 MENTOR WORLDWIDE LLC IN RUSSIA IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 697
• FIGURE 108 AZERBAIJAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 698
• FIGURE 109 CANDELA CORPORATION IN AZERBAIJAN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 699
• FIGURE 110 GEORGIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 700
• FIGURE 111 CANDELA CORPORATION IN GEORGIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 701
• FIGURE 112 LITHUANIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 702
• FIGURE 113 CANDELA CORPORATION IN LITHUANIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 703